Expression of the Complement Regulatory Proteins Decay Accelerating Factor (DAF, CD55), Membrane Cofactor Protein (MCP, CD46) and CD59 in the Normal Human Uterine Cervix and in Premalignant and Malignant Cervical Disease

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 1997 Nov 14

PMID 9358772

Citations 21

Authors

K L Simpson

A Jones

S Norman

C H Holmes

Affiliations

Soon will be listed here.

Abstract

The membrane-bound complement regulators decay-accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46), and CD59 are broadly expressed proteins that act together to protect host tissues from autologous complement. Comparison of expression profiles of these proteins between normal and pathological tissues could reveal a mechanism by which tumor cells evade complement-mediated killing. Expression of the regulators was therefore examined in the normal human uterine cervix, in cervical intraepithelial neoplasia (CIN; n = 23), and in cervical squamous carcinomas (n = 6). DAF and MCP were reciprocally expressed in normal ectocervical epithelium. MCP was confined predominantly to the basal and parabasal layers with more extensive expression in metaplastic squamous epithelium. An apparent expansion in MCP expression was observed in more severe premalignant lesions whereas cervical carcinoma were uniformly MCP positive. By contrast, DAF expression appeared unaltered in premalignant lesions and variable in carcinomas. However, increased DAF was observed in stromal cells directly adjacent to infiltrating tumor cells. A low molecular weight DAF product was detected in tumors, and preliminary evidence suggests this may be derived from stromal cells. Overall, changes in expression of C3 convertase regulators in both the stromal and epithelial compartments may be important for evasion of immune surveillance in cervical cancer.

Citing Articles

Receptors and Host Factors for Enterovirus Infection: Implications for Cancer Therapy.

Alekseeva O, Hoa L, Vorobyev P, Kochetkov D, Gumennaya Y, Naberezhnaya E Cancers (Basel). 2024; 16(18).

PMID: 39335111 PMC: 11430599. DOI: 10.3390/cancers16183139.

Complement Regulatory Protein CD46 Manifests a Unique Role in Promoting the Migration of Bladder Cancer Cells.

Nguyen T, Thanh H, Do M, Jung C Chonnam Med J. 2023; 59(3):160-166.

PMID: 37840671 PMC: 10570858. DOI: 10.4068/cmj.2023.59.3.160.

CD46 protects the bladder cancer cells from cetuximab-mediated cytotoxicity.

Do M, Thanh H, To P, Kim M, Moon C, Jung C Sci Rep. 2022; 12(1):22420.

PMID: 36575233 PMC: 9794803. DOI: 10.1038/s41598-022-27107-9.

Targeting the Complement Pathway in Malignant Glioma Microenvironments.

Zhu H, Yu X, Zhang S, Shu K Front Cell Dev Biol. 2021; 9:657472.

PMID: 33869223 PMC: 8047198. DOI: 10.3389/fcell.2021.657472.

Integrative Analysis of Complement System to Prognosis and Immune Infiltrating in Colon Cancer and Gastric Cancer.

Bao D, Zhang C, Li L, Wang H, Li Q, Ni L Front Oncol. 2021; 10:553297.

PMID: 33614473 PMC: 7886994. DOI: 10.3389/fonc.2020.553297.

References

Laemmli U . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. DOI: 10.1038/227680a0. View

Cervoni F, Oglesby T, Fenichel P, Dohr G, Rossi B, Atkinson J . Expression of decay-accelerating factor (CD55) of the complement system on human spermatozoa. J Immunol. 1993; 151(2):939-48. View

Price R, Boettcher B . The presence of complement in human cervical mucus and its possible relevance to infertility in women with complement-dependent sperm-immobilizing antibodies. Fertil Steril. 1979; 32(1):61-6. DOI: 10.1016/s0015-0282(16)44117-8. View

Towbin H, Staehelin T, Gordon J . Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979; 76(9):4350-4. PMC: 411572. DOI: 10.1073/pnas.76.9.4350. View

Sparrow R, McKenzie I . Hu Ly-m5: a unique antigen physically associated with HLA molecules. Hum Immunol. 1983; 7(1):1-15. DOI: 10.1016/0198-8859(83)90002-2. View

Sunderland C, Davies J, Stirrat G . Immunohistology of normal and ovarian cancer tissue with a monoclonal antibody to placental alkaline phosphatase. Cancer Res. 1984; 44(10):4496-502. View

Medof M, Walter E, Rutgers J, Knowles D, NUSSENZWEIG V . Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med. 1987; 165(3):848-64. PMC: 2188295. DOI: 10.1084/jem.165.3.848. View

Pesando J, Stucki M, Hoffman P . Altered expression of surface antigens with appearance of HLA class II molecules on a malignant human B-cell line. Hum Immunol. 1987; 19(4):235-43. DOI: 10.1016/0198-8859(87)90041-3. View

Cheung N, Walter E, Ratnoff W, Tykocinski M, Medof M . Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest. 1988; 81(4):1122-8. PMC: 329640. DOI: 10.1172/JCI113426. View

10.

Davis L, Patel S, Atkinson J, Lipsky P . Decay-accelerating factor functions as a signal transducing molecule for human T cells. J Immunol. 1988; 141(7):2246-52. View

11.

Lublin D, Atkinson J . Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol. 1989; 7:35-58. DOI: 10.1146/annurev.iy.07.040189.000343. View

12.

McNearney T, BALLARD L, Seya T, Atkinson J . Membrane cofactor protein of complement is present on human fibroblast, epithelial, and endothelial cells. J Clin Invest. 1989; 84(2):538-45. PMC: 548913. DOI: 10.1172/JCI114196. View

13.

Seya T, Atkinson J . Functional properties of membrane cofactor protein of complement. Biochem J. 1989; 264(2):581-8. PMC: 1133618. DOI: 10.1042/bj2640581. View

14.

Holmes C, Simpson K, WAINWRIGHT S, Tate C, Houlihan J, Sawyer I . Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy. J Immunol. 1990; 144(8):3099-105. View

15.

Seya T, Hara T, Matsumoto M, Akedo H . Quantitative analysis of membrane cofactor protein (MCP) of complement. High expression of MCP on human leukemia cell lines, which is down-regulated during cell differentiation. J Immunol. 1990; 145(1):238-45. View

16.

Nose M, Katoh M, Okada N, KYOGOKU M, Okada H . Tissue distribution of HRF20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo. Immunology. 1990; 70(2):145-9. PMC: 1384184. View

17.

Naniche D, Cervoni F, Wild T, Rossi B, Rabourdin-Combe C, Gerlier D . Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol. 1993; 67(10):6025-32. PMC: 238023. DOI: 10.1128/JVI.67.10.6025-6032.1993. View

18.

Dorig R, Marcil A, Chopra A, Richardson C . The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell. 1993; 75(2):295-305. DOI: 10.1016/0092-8674(93)80071-l. View

19.

Nowicki B, Hart A, Coyne K, Lublin D, Nowicki S . Short consensus repeat-3 domain of recombinant decay-accelerating factor is recognized by Escherichia coli recombinant Dr adhesin in a model of a cell-cell interaction. J Exp Med. 1993; 178(6):2115-21. PMC: 2191283. DOI: 10.1084/jem.178.6.2115. View

20.

Simpson K, Houlihan J, Holmes C . Complement regulatory proteins in early human fetal life: CD59, membrane co-factor protein (MCP) and decay-accelerating factor (DAF) are differentially expressed in the developing liver. Immunology. 1993; 80(2):183-90. PMC: 1422187. View